Beranda › Limfoma Zona Marginal › Florida
Uji klinis Limfoma Zona Marginal di Florida
15 studi untuk Limfoma Zona Marginal mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06350318A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Jacksonville, Jacksonville
- Mount Sinai Medical Center Braman Comprehensive Cancer Center, Miami
- Tampa General Hospital Cancer Institute, Tampa
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
- UM Sylvester Comprehensive Cancer Center at Coral Springs, Coral Springs
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
- dan 7 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT04840602Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
- University of Miami, Miami
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05296070A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Boca Raton Clinical Research (BRCR) Global, Plantation
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06149286Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Jacksonville
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Mayo Clinic, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Miami, Miami
- Florida Cancer Specialists, Sarasota
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
- University of Miami, Miami
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT05700149Study of SGR-1505 in Mature B-Cell Neoplasms
- Napa Research, Pompano Beach
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Mayo Clinic in Florida, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT06191887AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Mount Sinai Comprehensive Cancer Center, Miami Beach
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Jacksonville
- Massive Bio SYNERGY-AI site, Miami
- Massive Bio SYNERGY-AI site, Tampa
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
- University of Miami, Miami
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT06796998A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Florida Cancer Specialists, Sarasota
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.